[UFT-therapy and UFTM therapy--comparison of survivals in the patients with Borrmann type 4 gastric cancer treated either with UFTM-chemotherapy or operation].
First, UFT therapy was designed on the basis of pharmacokinetics of UFT for the treatment of patients with gastric cancer. Then, UFTM therapy was established in combination of UFT and mitomycin C. A total of 22 patients with Borrmann type 4 gastric cancer were treated with UFTM therapy. clinical responses were observed in 15 patients out of 22, with a response rate of 68.2%. Survival time was compared between UFTM and surgical treatment in the patients with Borrmann type 4 gastric cancer. As a result, no difference was observed between the two groups in the survivals. Accordingly, it was considered that there was no evidence which supports an alternative treatment of either UFTM or operation, except for the case of far-advanced gastric cancer.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D005743:Gastrectomy / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D004338:Drug Combinations; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil